To appropriately address this issue, a study where TAZ and YAP are evaluated together with further candidate biomarkers has been planned, envisioning the concomitant assessment of i) TAZ/YAP targets (Axl and CTGF [2]), ii) Hippo-dependent and independent cues that feed TAZ/YAP activation, including mechanisms involved in cell-cell adhesion and apical-basal polarity [2], mechanotransduction [21], RHO GTPases and the mevalonate pathway [22], and Wnt signaling [23], and iii) Markers of specific cellular components in the tumor microenvironment (e.g. CAFs, immune cell subsets). This evidence concerns the gene AXL and neoplasm.